Authors: Dunford, JE Thompson, K Coxon, FP Luckman, SP Hahn, FM Poulter, CD Ebetino, FH Rogers, MJ

Citation: Je. Dunford et al., Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro nd inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates, J PHARM EXP, 296(2), 2001, pp. 235-242

Authors: Rogers, MJ Frith, JC Luckman, SP Coxon, FP Benford, HL Monkkonen, J Auriola, S Chilton, KM Russell, RGG

Citation: Mj. Rogers et al., Molecular mechanisms of action of bisphosphonates, BONE, 24(5), 1999, pp. 73S-79S

Authors: Russell, RGG Rogers, MJ Frith, JC Luckman, SP Coxon, FP Benford, HL Croucher, PI Shipman, C Fleisch, HA

Citation: Rgg. Russell et al., The pharmacology of bisphosphonates and new insights into their mechanismsof action, J BONE MIN, 14, 1999, pp. 53-65

Authors: Fisher, JE Rogers, MJ Halasy, JM Luckman, SP Hughes, DE Masarachia, PJ Wesolowski, G Russell, RGG Rodan, GA Reszka, AA

Citation: Je. Fisher et al., Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro, P NAS US, 96(1), 1999, pp. 133-138